
Indian Drugmakers Unfazed by Trump's Tariff Threat
The story in brief
Indian pharmaceutical firms dominate the U.S. generic drug market due to their ability to produce affordable medicines. The U.S. system rewards the cheapest and safest suppliers, with Asian companies excelling. Despite President Trump’s threat of steep tariffs on imported generics, Indian firms see little incentive to shift production to the U.S. due to lower profit margins and no room to absorb tariffs.